Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
Arcus Biosciences (NYSE:RCUS) announced four accepted abstracts for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, November 6-10, 2024. The key highlight is a late-breaking poster presenting data from ARC-10, including overall survival results for domvanalimab plus zimberelimab in front-line NSCLC patients. The study evaluates this combination versus zimberelimab or chemotherapy in patients with PD-L1-high locally advanced or metastatic NSCLC.
Additionally, an oral presentation will showcase data from an Investigator Sponsored Trial examining domvanalimab and zimberelimab in anti-PD-1 refractory hepatocellular carcinoma. The company will discuss ARC-10 results during its earnings call on November 6, 2024.
Arcus Biosciences (NYSE:RCUS) ha annunciato quattro abstract accettati per la presentazione al Congresso Annuale della Society for Immunotherapy of Cancer (SITC) a Houston, dal 6 al 10 novembre 2024. Il punto saliente è un poster presentato all'ultimo minuto che mostra i dati di ARC-10, inclusi i risultati di sopravvivenza complessiva per domvanalimab più zimberelimab in pazienti con NSCLC in fase iniziale. Lo studio valuta questa combinazione rispetto a zimberelimab o chemioterapia in pazienti con NSCLC localmente avanzato o metastatico ad alto PD-L1.
Inoltre, una presentazione orale mostrerà i dati di uno Studio Sponsorizzato dall'Investitore che esamina l'uso di domvanalimab e zimberelimab nel carcinoma epatocellulare refrattario anti-PD-1. L'azienda discuterà i risultati di ARC-10 durante la sua chiamata sugli utili il 6 novembre 2024.
Arcus Biosciences (NYSE:RCUS) anunció cuatro resúmenes aceptados para su presentación en el Congreso Anual de la Society for Immunotherapy of Cancer (SITC) en Houston, del 6 al 10 de noviembre de 2024. El punto destacado es un póster de última hora que presenta datos de ARC-10, incluyendo los resultados de supervivencia global para domvanalimab más zimberelimab en pacientes con NSCLC de primera línea. El estudio evalúa esta combinación frente a zimberelimab o quimioterapia en pacientes con NSCLC localmente avanzado o metastásico de alto PD-L1.
Además, se dará una presentación oral que mostrará datos de un Estudio Patrocinado por Investigadores que examina domvanalimab y zimberelimab en carcinoma hepatocelular refractario anti-PD-1. La compañía discutirá los resultados de ARC-10 durante su llamada de ganancias el 6 de noviembre de 2024.
Arcus Biosciences (NYSE:RCUS)는 2024년 11월 6일부터 10일까지 휴스턴에서 열리는 암 면역 치료학회 (SITC) 연례 회의에서 발표할 수락된 네 개의 초록을 발표했습니다. 주요 하이라이트는 1차 NSCLC 환자에서 도르바나리맙과 짐버렐리맙 병용 투여에 대한 전체 생존 결과를 포함하는 ARC-10의 데이터를 제시하는 늦게 발표된 포스터입니다. 이 연구는 PD-L1 발현이 높은 지역 진행성 또는 전이성 NSCLC 환자에서 이 조합과 짐버렐리맙 또는 화학요법을 비교 평가합니다.
추가로, 구두 발표에서는 항-PD-1 치료에 반응하지 않는 간세포 암에서 도르바나리맙과 짐버렐리맙을 조사하는 연구자 후원 시험의 데이터를 보여줄 예정입니다. 회사는 2024년 11월 6일에 예정된 실적 발표에서 ARC-10의 결과를 논의할 것입니다.
Arcus Biosciences (NYSE:RCUS) a annoncé quatre résumés acceptés pour présentation lors de la Réunion Annuelle de la Society for Immunotherapy of Cancer (SITC) à Houston, du 6 au 10 novembre 2024. Le point fort est un poster à la dernière minute présentant des données de ARC-10, y compris les résultats de survie globale pour le domvanalimab associé au zimberelimab chez des patients atteints de NSCLC en première ligne. L'étude évalue cette combinaison par rapport au zimberelimab ou à la chimiothérapie chez des patients présentant un NSCLC localement avancé ou métastatique avec un taux élevé de PD-L1.
De plus, une présentation orale mettra en avant des données d'un essai sponsorisé par un chercheur examinant le domvanalimab et le zimberelimab dans le carcinome hépatocellulaire réfractaire à l'anti-PD-1. L'entreprise discutera des résultats d'ARC-10 lors de son appel de résultats le 6 novembre 2024.
Arcus Biosciences (NYSE:RCUS) gab bekannt, dass vier akzeptierte Abstracts auf dem Jahrestreffen der Society for Immunotherapy of Cancer (SITC) in Houston vom 6. bis 10. November 2024 präsentiert werden. Das Hauptaugenmerk liegt auf einem späten Poster, das Daten aus ARC-10 präsentiert, einschließlich der Gesamtüberlebensraten für Domvanalimab plus Zimberelimab bei NSCLC-Patienten in der Erstlinie. Die Studie bewertet diese Kombination im Vergleich zu Zimberelimab oder Chemotherapie bei Patienten mit PD-L1-hohem, lokal fortgeschrittenem oder metastasiertem NSCLC.
Zusätzlich wird eine mündliche Präsentation Daten aus einer vom Investigator geförderten Studie präsentieren, die Domvanalimab und Zimberelimab bei anti-PD-1-refraktärem hepatocellulärem Karzinom untersucht. Das Unternehmen wird die Ergebnisse von ARC-10 während seines Gewinnanrufs am 6. November 2024 erörtern.
- None.
- None.
- Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC), will be presented in a late-breaking poster presentation
- An oral presentation will highlight data from an Investigator Sponsored Trial for domvanalimab and zimberelimab in anti-PD-1 refractory hepatocellular carcinoma, demonstrating further proof of concept for the Fc-silent anti-TIGIT antibody domvanalimab
- Arcus will discuss the ARC-10 results in more detail on its earnings call at 2:00 PM PT / 5:00 PM ET on Wednesday, November 6, 2024
A late-breaking poster presented by Melissa L. Johnson, M.D., director, lung cancer research, Sarah Cannon Research Institute, will highlight safety and efficacy data, including objective response rate, progression-free survival and overall survival from ARC-10. This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus zimberelimab or chemotherapy, in patients with front-line locally advanced or metastatic squamous or non-squamous NSCLC with a PD-L1 tumor proportion score of ≥
“The ARC-10 late-breaking poster will include the first overall survival results to be reported for the combination of domvanalimab and zimberelimab, and further build on the evidence that an Fc-silent anti-TIGIT antibody may provide differentiated efficacy and safety relative to the Fc-enabled anti-TIGIT antibodies,” said Terry Rosen, Ph.D., chief executive officer of Arcus.
Four Accepted Abstracts Will Be Presented
Study |
Title |
Abstract Number |
Session Type |
Session Date & Time |
Domvanalimab (Fc-silent anti-TIGIT monoclonal antibody) plus Zimberelimab (anti-PD-1 antibody) |
||||
ARC-10 |
Randomized Study of Domvanalimab Combined with Zimberelimab in Front-Line, PD-L1 High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Results from ARC-10 |
1461 |
Late-Breaking Poster Session |
11/8/2024, 9:00 AM – 7:00 PM CST |
Investigator Sponsored Trial |
Dual TIGIT and PD-1 Blockade With Domvanalimab Plus Zimberelimab in Hepatocellular Carcinoma Refractory to Anti-PD-1 Therapies |
603 |
Oral Presentation, Concurrent Session 107c: Timing and Combination of Systemic Therapies in Solid Cancers |
11/8/2024, 3:50 PM – 5:25 PM CST |
|
TIGIT Blockade by Monoclonal Antibodies Promotes T Cell Activation and Anti-Tumor Activity That is Not Dependent on a Functionalized Fc Domain |
507 |
Poster Session |
11/8/2024, 9:00 AM – 7:00 PM CST |
Etrumadenant (A2a/A2b receptor antagonist) |
||||
ARC-9 |
The Adenosine Receptor Antagonist Etrumadenant Reduces Tumor Adenosine-Regulated NR4A Gene Expression and Increases mCRC Inflammation in Patients from the ARC-9 Trial |
52 |
Poster Session |
11/9/2024, 9:00 AM – 8:30 PM CST |
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Domvanalimab, zimberelimab and etrumadenant are investigational molecules. Arcus and Gilead have not received approval from any regulatory authority for any commercial use globally, and their safety and efficacy have not been established.
Forward Looking Statements
This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Rosen’s quote and statements regarding: the mechanisms of action for any of our investigational products; and current or future combinations involving our investigational products, including the potential benefit or effect of any such combinations. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks associated with: interim data not being replicated in future studies evaluating the same investigational molecules or regimen; the unexpected emergence of adverse events or other undesirable side effects in Arcus’s investigational products, including domvanalimab and zimberelimab; risks associated with the manufacturing or supplying product for such clinical trials; Arcus’s dependence on the collaboration with Gilead for the successful development and commercialization of its optioned molecules; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the “Risk Factors” section of Arcus’s most recent periodic report filed with the
The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030097614/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Affairs
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
What are the key findings being presented at SITC 2024 for Arcus Biosciences (RCUS)?
When and where will Arcus Biosciences (RCUS) present their ARC-10 study results?
What is the target patient population for the Arcus Biosciences (RCUS) ARC-10 study?